One example is the prescription of statins (HMG-CoA reductase inhibitors) as primary prevention for CHD, which has attracted controversy due to the potential high up-front cost but a potential overall net saving due to reduced future CHD costs as well as wider cardiovascular disease (CVD) costs such as those of strokes avoided [1]. This evidence concerns the gene HMGCR and coronary artery disorder.